Transjugular intrahepatic portosystemic shunt by using covered stents of different diameters for the treatment of esophagogastric varices rupture with bleeding / 介入放射学杂志

Objective To assess the efficacy and safety of different diameter covered stents used in transjugular intrahepatic portosystemic shunt (TIPS) for esophagogastric varices with bleeding (EGVB). Methods The clinical data of 68 patients with portal hypertension due to cirrhosis, who received TIPS for EGVB during the period from Desember 2010 to February 2015, were retrospectively analyzed. Among the 68 patients, covered stent with diameter of 7mm was used in 30 (small stent group) and covered stent with diameter of 8mm was employed in 38 (big stent group). Using Kaplan-Meier method, the cumulative digestive tract no-rebleeding rate, the patency rate of shunt and the survival rate of both groups were analyzed. Logrank test was used to make comparison between the two groups, and chi-square test was conducted to compare the incidence of hepatic encephalopathy between the two groups. Results The operative success rate was 100％ in 68 patients. The patients were followed up for 0.1-52.3 months, with a mean of (19.4±16.0) months. The 3-, 6-and 12-month cumulative digestive tract no-rebleeding rates were 86.54％, 79.30％ and 74.90％ respectively in the small stent group, which were 91.87％, 85.93％ and 81.63％ respectively in the big stent group, but the differences between the two groups were not statistically significantly (X2=0.05, P=0.83). The 3-, 6-and 12-month cumulative patency rates of shunt in the small stent group were 95.00％, 80.19％ and 70.17％ respectively, which in the big stent group were 96.15％, 91.97％ and 81.07％ respectively, and no statistically significant differences existed between the two groups (X2=0.40, P=0.53). The 3-, 12-, 24-and 48-month cumulative survival rates in the small stent group were 93.33％, 86.67％, 75.11％ and64.38％ respectively, while those in the big stent group were 97.37％, 94.23％, 88.68％ and 76.02％ respectively, and the differences between the two groups were not statistically significantly (X2=2.21, P=0.14). Postoperative hepatic encephalopathy occurred in 15 patients (15/68, 22.06％), the incidences of hepatic encephalopathy in the small stent group and in the big stent group were 20.00％ (6/30) and 23.68％ (9/38) respectively, the difference between the two groups was not statistically significantly (X2=0.13, P=0.72). Conclusion Compared with the use of 7mm covered stent, the use of 8mm covered stent in TIPS neither can improve the curative effect nor can reduce the incidence of hepatic encephalopathy.

Transjugular intrahepatic portasystemic shunt with Viatorr covered stent / 中国介入影像与治疗学

Objective To assess the efficacy and safety of transjugular intrahepatic portasystemic shunt (TIPS) with Viatorr covered stent in patients with portal hypertension-related complications.Methods Clinical data of 8 patients with por-tal hypertension-related complications were analyzed retrospectively.All the cases received TIPS with Viatorr covered stent.After the operation,the followed up was used to evaluate the therapeutic effect of TIPS by enhanced CT scan.Results All the operations of TIPS were technically successful.And all the cases were treated with Viatorr covered stents with diameter of 8 mm and covered segment length of 50-80 mm.For 1 case with cavernous transformation of portal vein,a 8 mm×40 mm E-Luminexx bare stent was implanted in the portal vein side.For 1 case with hepatic vein stenosis,a 8 mm× 40 mm Fluency covered stent was implanted in the hepatic vein side.After the operation,the portal pressure reduced from (33.08 [29.32,40.22])mmHg (preoperative) to (23.31 [21.43,26.51])mmHg (postoperative) with statistical difference (Z=-2.52,P=0.012).The patients were followed up for 1.1-7.7 months,and all the patients were alive without complications of portal hypertension.There were 2 cases with mild hepatic encephalopathy after operation.During the reexamination time of 1-7.7 months,all TIPS shunts remained patency.Conclusion TIPS with Viatorr stent is a safe and effective treatment for patients with portal hypertension-related complications.

Transjugular intrahepatic portasystemic shunt with Viatorr covered stent / 中国介入影像与治疗学

Objective To assess the efficacy and safety of transjugular intrahepatic portasystemic shunt (TIPS) with Viatorr covered stent in patients with portal hypertension-related complications.Methods Clinical data of 8 patients with por-tal hypertension-related complications were analyzed retrospectively.All the cases received TIPS with Viatorr covered stent.After the operation,the followed up was used to evaluate the therapeutic effect of TIPS by enhanced CT scan.Results All the operations of TIPS were technically successful.And all the cases were treated with Viatorr covered stents with diameter of 8 mm and covered segment length of 50-80 mm.For 1 case with cavernous transformation of portal vein,a 8 mm×40 mm E-Luminexx bare stent was implanted in the portal vein side.For 1 case with hepatic vein stenosis,a 8 mm× 40 mm Fluency covered stent was implanted in the hepatic vein side.After the operation,the portal pressure reduced from (33.08 [29.32,40.22])mmHg (preoperative) to (23.31 [21.43,26.51])mmHg (postoperative) with statistical difference (Z=-2.52,P=0.012).The patients were followed up for 1.1-7.7 months,and all the patients were alive without complications of portal hypertension.There were 2 cases with mild hepatic encephalopathy after operation.During the reexamination time of 1-7.7 months,all TIPS shunts remained patency.Conclusion TIPS with Viatorr stent is a safe and effective treatment for patients with portal hypertension-related complications.

Cryoplasty for the treatment of iliac artery stenosis in canine model / 中华放射学杂志

Objective To evaluate the treatment effect of balloon angioplasty and cryoplasty on iliac artery stenosis in canine model.Methods Canine models of iliac artery stenosis were established with surgical ligation and transfixion.Models were randomly divided into two groups:iliac artery stenosis treated by cryoplasty (n =8) and by balloon angioplasty (n =8).The degree of iliac artery stenosis of two model groups was assessed by digital subtraction angiography (DSA) immediately and two weeks after the angioplasties.Then all the dogs were executed for pathological observation of the target vessels.Results Sixteen canine models of iliac artery stenosis were established by surgical ligation and transfixion method with 100％ success rate.DSA showed there was (45 ± 12)％ of residual artery stenosis in the cryoplasty group immediately after surgery,while it was (39-12)％ in the balloon angioplasty group,and there was no significant difference between them(t =3.183,P ＞ 0.05).The artery stenosis of cryoplasty group was (48 ± 17) ％ after two weeks and not significantly different from that after surgery immediately (t =-1.271,P ＞ 0.05).The artery stenosis of balloon angioplasty group was (67 ± 13)％ after two weeks,and it was significantly higher compared with at after surgery immediately (t =-6.666,P ＜ 0.01).The degree of vascular stenosis in balloon angioplasty group was severer than that in cryoplasty group two weeks after angiography(P =0.041).The pathological examination showed artery intimal hyperplasia in cryoplasty group was milder than that in balloon angioplasty group and neointimal content of collagen in cryoplasty group was less than that in balloon angioplasty group.Conclusions The animal models of iliac artery stenosis were established successfully with surgical ligation and transfixion by damaging the intima and media of arterial wall.Compared with balloon angioplasty,the cryoplasty was able to inhibit proliferation of intimal and reduce collagen synthesis to prevent the iliac artery restenosis.

Study on the Antihepatocarcinoma Activity and the Acute Toxicity of Aclacimomycin-A Solid Lipids Nanoparticle for Injection in Mice in Vivo / 中国药房

OBJECTIVE:To study the antihepatocarcinoma activity and toxicity of Aclacimomycin-A solid lipids nanoparticle for injection(ACM-SLN)in nude mice in vivo with ACM for injection as the reference preparation.METHODS:The nude mice were divided into control group,ACM group and ACM-SLN group after tumor transplantation,which were injected with the corresponding medicine before the tumor-inhibition rates of which were calculated,which were then injected with ACM and ACM-SLN,respectively before the LD50 of mice were calculated.RESULTS:Compared with the control group,the tumor inhibition rates of ACM-SLN group and ACM group were 78.4%and 38.8%,respectively,the LD50 of which were 16.3 mg/kg and 18.0mg/kg,respectively.CONCLUSION:The ACM-SLN is superior to ACM in terms of the anti-tumor effect while without the increase of toxicity.

Determination of Two Ingredients in Calamine and Menthol Lotion by GC-MS / 中国药房

OBJECTIVE:To establish a GC-MS assay for determination of the contents of phenol and menthol in calamine and menthol lotion.METHODS:Using DM-5elastic quartz capillary as separation column,I-octanol as internal standard,phenol and menthol were detected separately under the70℃～150℃step-up hyperthermic condition to select the ion fragment peaks with M/Z of94and71.RESULTS:Phenol and menthol were good linear within1.092～21.840?g/ml(r=0.9998)and1.194～9.552?g/ml(r=0.9999).Recoveries were100.2%(RSD=1.34%)and100.4%(RSD=0.74%)respective?ly.CONCLUSION:The method is quick and accurate with highly repeatability and specificity and it is adequate for contents determination and quality control for this preparation.

Content Determination of Costunolide in Liqifuwei Oral Liquid by RP-HPLC / 中国药房

OBJECTIVE:To establish a RP-HPLC method for content determination of costunolide in Liqifuwei oral liquid.METHODS:The assay was performed on a Luna C 18 column by UV detector at the wavelength of225nm with methanol-water(72∶28)as the mobile phase at the flow rate of1.0ml/min.RESULTS:The amount of costunolide was linear with its area over the range from0.2?g～2.0?g(r=0.9996),the average recovery was98.4%(RSD=0.85%).CONCLUSION:The present method is convenient,sensitive and accurate with good reproducibility and can be used for the quality control of Liqifuwei oral liquid.

Determination of the Concentrations of Salicylic Acid in Serum With RP-HPLC and Its Application / 中国药房

OBJECTIVE:To develop a RP-HPLC method for the determination of salicylic acid in serum and to apply this method to the pharmacokinetic and bioavailability study of salycylic acid in compound aspirin preparations.METHODS:Waters2690HPLC instrument was used with Diamonsil C 18 column(5?m,250mm?4.6mm)as stationary phase and methanol-ace?tonitrile-0.2%phosphoric acid(18∶32∶50)as mobile phase at a flow rate of1.0ml/min,and the detective wavelength was237nm.RESULTS:Calibration curve of salicylic acid was linear in the range of0.40～101.00?g/ml(r=0.9999).CONCLUS_ ION:The method is simple,sensitive,rapid and suitable for pharmacokinetic and bioavailability study of salicylic acid.

Study on Optimizing Extraction Process for Ginsenoside With Orthogonal Design / 中国药房

OBJECTIVE:To study the extraction process of ginsenoside.METHODS:The optimal extraction process was selected with the orthogonal design.The content of ginsenoside in ginseng was determined by UV-Spectrophotometry.RESUL_TS:The amount and concentration of alcohol and extraction time showed significant influence on extract obtained.CONCLUSI_ON:The optimal extraction process is as follows:adding 75% alcohol into crude ginseng(6∶1 in weight) and extracting 6 times for 45 min each extraction.

Determination of the Concentration of Valproic Acid in Serum With RP-HPLC / 中国药房

OBJECTIVE:To determine the concentration of valproic acid in serum.METHODS:Determination was performed with RP-HPLC with methanol:water(70∶30) as mobile phase,?-bromoacetophenone as deriving agent and cyclohexanecarboxylic acid as internal standard,and detected at wavelength 248nm.RESULTS:The calibrating curve of valproic acid was linear in the range of 14.47～248.0?g/ml.CONCLUSION:The method was convenient,rapid,accurate and suitable for TDM.

Determination of Propafenone Concentration in Human Plasma by High-performance Liquid Chromatography / 中国药房

A rapid and simple HPLC method for determination of propafenone concentration in human plasma is described. Dyclonine hydrochloride was used as an internal standard. YWG-C_(18) column(10?m)was used with a mobile phase of methanol-acetonitrile-0.05mol/L acetate buffer(pH 4.02)-diethylamine(45.5:19.5:35). Detection was performed by ultraviolet absorption at 254nm. The detection limit of propafenone waw 5ng (S/W=3)or 25ng/ml in plasma. Assay linearity was shown in a range of 50～500ng/ml with a regression coefficient of 0.9993. The recovery(n=4)was 100.5％,the CV of within-day and day-to-day being less than 3％. No interference was found from endogenous compounds or commonly used drugs. So it can be applied to pharmacokinetic studies and therapeutic monitoring.